📊 BMRA Key Takeaways
Investment Thesis
Biomerica is a severely distressed diagnostic company with stagnant revenue ($2.6M), massive operating losses (-96.1% margin), and persistent cash burn (-$1.3M operating cash flow). Despite modest liquidity (3.25x current ratio), the company is operationally insolvent with no clear path to profitability or sustainable revenue growth.
BMRA Strengths
- Strong current ratio of 3.25x provides near-term liquidity buffer
- Zero long-term debt reduces financial leverage risk
- Cash position of $2.5M provides runway for operations
BMRA Risks
- Flat revenue with zero growth trajectory indicates severe market/competitive headwinds
- Negative operating margin of -96.1% indicates business model is fundamentally broken
- Persistent operating cash burn of -$1.3M will exhaust cash reserves within 1.9 years at current rate
- Net losses of -$1.3M on only $2.6M revenue demonstrates inability to control costs
- Low gross margin of 18.4% leaves minimal buffer for operating expenses
- Negative ROE and ROA show value destruction across equity and assets
Key Metrics to Watch
- Quarterly revenue trend - any indication of stabilization or contraction acceleration
- Operating cash flow depletion rate and runway to insolvency
- Gross margin sustainability and cost structure improvements
- Cash balance trajectory and potential need for financing or restructuring
- Form 4 insider trading activity patterns - selling suggests lack of confidence
BMRA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.25x current ratio provides a solid financial cushion.
BMRA Profitability Ratios
BMRA vs Default Sector
How BIOMERICA INC compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BMRA Balance Sheet & Liquidity
BMRA 5-Year Financial Trend
5-Year Trend Summary: BIOMERICA INC's revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $-2.84 indicates the company is currently unprofitable.
BMRA Growth Metrics (YoY)
BMRA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.2M | $2.0K | $-0.06 |
| Q1 2026 | $1.4M | $2.0K | $0.00 |
| Q3 2025 | $1.0M | -$950.0K | $-0.06 |
| Q2 2025 | $1.6M | -$950.0K | $-0.06 |
| Q1 2025 | $1.7M | -$1.1M | $-0.07 |
| Q3 2024 | $1.0M | -$1.1M | $-0.11 |
| Q2 2024 | $1.5M | -$1.1M | $-0.09 |
| Q1 2024 | $1.6M | -$1.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BMRA Capital Allocation
BMRA SEC Filings
Access official SEC EDGAR filings for BIOMERICA INC (CIK: 0000073290)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMRA
What is the AI rating for BMRA?
BIOMERICA INC (BMRA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMRA's key strengths?
Strong current ratio of 3.25x provides near-term liquidity buffer. Zero long-term debt reduces financial leverage risk.
What are the risks of investing in BMRA?
Flat revenue with zero growth trajectory indicates severe market/competitive headwinds. Negative operating margin of -96.1% indicates business model is fundamentally broken.
What is BMRA's revenue and growth?
BIOMERICA INC reported revenue of $2.6M.
Does BMRA pay dividends?
BIOMERICA INC does not currently pay dividends.
Where can I find BMRA SEC filings?
Official SEC filings for BIOMERICA INC (CIK: 0000073290) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMRA's EPS?
BIOMERICA INC has a diluted EPS of $-0.48.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.